Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 32,907 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo/Control Clear all
Terminated Phase 2 Interventional Results available

Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

NCT02258464
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Placebo (saline), Background hormonal therapy
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
11
States / cities
Bakersfield, California • La Jolla, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 21, 2026, 1:21 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis

NCT04851964
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Experimental: Tezepelumab, Placebo, Mometasone furoate or equivalent intranasal corticosteroid
Biological · Other · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
21
States / cities
Birmingham, Alabama • Bakersfield, California • Newport Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 21, 2026, 1:21 AM EDT
Completed Phase 1 Interventional Results available

Study of Erenumab (AMG 334) in Women With Hot Flashes

NCT01890109
View directory record Official record
Conditions
Vasomotor Symptoms; Hot Flashes
Interventions
Erenumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
San Diego, California • Miami, Florida • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 21, 2026, 1:21 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects

NCT00903409
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Simvastatin + Lovaza® (omega-3-acid ethyl esters)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
40
States / cities
Mobile, Alabama • Encinitas, California • Fresno, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2017 · Synced Oct 21, 2026, 1:21 AM EDT
Recruiting Phase 2 Interventional

A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol

NCT07199309
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
MAR001, Placebo
Drug
Lead sponsor
Marea Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 21, 2026, 1:21 AM EDT
Completed Phase 2Phase 3 Interventional

A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix

NCT00264732
View directory record Official record
Conditions
Uterine Cervical Dysplasia
Interventions
Amolimogene, Placebo
Drug · Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
13 Years to 25 Years · Female only
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Oct 21, 2026, 1:21 AM EDT
Not listed Phase 1Phase 2 Interventional

Trial of Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease

NCT01099332
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Gastro-retentive zinc cysteine tablet, Tablet identical physically to active comparator containing some lactose
Other
Lead sponsor
Adeona Pharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Clearwater, Florida • Holiday, Florida • Port Richey, Florida
Source: ClinicalTrials.gov public record
Updated Jan 28, 2011 · Synced Oct 21, 2026, 1:21 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial of Leptin Replacement Therapy in Patients With Lipodystrophy

NCT00896298
View directory record Official record
Conditions
Hypoleptinemia, Generalized Lipodystrophy, Partial Lipodystrophy, Insulin Resistance
Interventions
Leptin, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 21, 2026, 1:21 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)

NCT01034163
View directory record Official record
Conditions
Hodgkin's Lymphoma
Interventions
Panobinostat, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
13
States / cities
Los Angeles, California • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2016 · Synced Oct 21, 2026, 1:21 AM EDT
Completed Phase 4 Interventional Results available

Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet

NCT00735787
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo, Adalimumab
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Little Rock, Arkansas • Bakersfield, California • Macon, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2010 · Synced Oct 21, 2026, 1:21 AM EDT
Completed Phase 1 Interventional

A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL

NCT03931993
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo comparator, Grass MATA MPL
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
4
States / cities
Edison, New Jersey • Ocean City, New Jersey • Springfield, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 21, 2026, 1:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tick-borne Illness and Clothing Study

NCT01454414
View directory record Official record
Conditions
Tick Bites, Tick-borne Illness
Interventions
Permethrin Impregnated Uniforms
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 21, 2026, 1:21 AM EDT
Terminated Phase 3 Interventional

Study of Epratuzumab in Systemic Lupus Erythematosus

NCT00111306
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
epratuzumab
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
13
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2011 · Synced Oct 21, 2026, 1:21 AM EDT
Active, not recruiting Phase 3 Interventional Results available

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

NCT02511106
View directory record Official record
Conditions
Stage IB-IIIA Non-small Cell Lung Carcinoma
Interventions
AZD9291 80 mg/40 mg, Placebo AZD9291 80 mg/40 mg, Open-label AZD9291 80 mg/40 mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
23
States / cities
Los Angeles, California • Santa Monica, California • Santa Rosa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 21, 2026, 1:21 AM EDT
Completed Phase 2Phase 3 Interventional Results available

An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy

NCT00505284
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
Placebo, E2007 (2 mg), E2007 (4 mg), E2007 (6 mg), E2007 (8 mg)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Oct 21, 2026, 1:21 AM EDT
Terminated Early Phase 1 Interventional

Vitamin D and Cocaine Administration

NCT04826133
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Calcitriol, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
30 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 21, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)

NCT03558152
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
UTTR1147A, UTTR1147A Placebo, Vedolizumab, Vedolizumab Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Greenville, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 21, 2026, 1:21 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Targeting Aging With a Ketone Ester for Function in Frailty

NCT06645847
View directory record Official record
Conditions
Frail Elderly, Aging, Immune Function, Muscle Function
Interventions
Ketone ester, Placebo Comparator: Non-ketone placebo
Other
Lead sponsor
Buck Institute for Research on Aging
Other
Eligibility
65 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
3
States / cities
Novato, California • Farmington, Connecticut • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 1:21 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease

NCT03761849
View directory record Official record
Conditions
Huntingtons Disease
Interventions
RO7234292, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
25 Years to 65 Years
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 21, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Results available

A Study of Oxytocin in Children and Adolescents With Autistic Disorder

NCT01308749
View directory record Official record
Conditions
Autism
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 21, 2026, 1:21 AM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)

NCT02312258
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Placebo, Ixazomib
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
23
States / cities
Fountain Valley, California • Los Angeles, California • Oceanside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 21, 2026, 1:21 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma

NCT03215758
View directory record Official record
Conditions
Asthma
Interventions
QAW039, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
42
States / cities
Flagstaff, Arizona • Phoenix, Arizona • Huntington Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 21, 2026, 1:21 AM EDT
Terminated Phase 2 Interventional Results available

An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma

NCT02219048
View directory record Official record
Conditions
Asthma
Interventions
Placebo, PF-03715455
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 21, 2026, 1:21 AM EDT
Terminated Phase 3 Interventional

Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

NCT01002248
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Perifosine, Perifosine Placebo, Bortezomib, Dexamethasone
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
39
States / cities
La Verne, California • San Francisco, California • San Pablo, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2018 · Synced Oct 21, 2026, 1:21 AM EDT